Death clinical trials

Explore recruiting death clinical trials.

Recruiting death studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Death trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Randomized open-label controlled trial evaluating a single-dose intravenous Dalbavancin versus standard antibiotic therapy during catheterrelated bloodstream infections due to Staphylococcus aureus [DALICATH]

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Programmed death ligand 1 (PD-L1) PET imaging in patients with (Diffuse) Large B-cell Lymphoma who are treated with CD19-directed CAR T-cell therapy: a pilot study

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2, first-in-human, two-part, open-label clinical trial of intravenous administration of CTL-002 given as monotherapy and/or in combination with an anti-PD-1 checkpoint inhibitor in subjects with advanced-stage, relapsed/refractory solid tumors.

Germany, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

PLATFORM - A PLATFORM TRIAL, EVALUATING NEW DRUGS OR COMBINATION IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Mannitol versus normal saline in brain death donors and recipients of kidney allograft on delayed graft function (MAVERICK) – A double-blinded, placebo-controlled randomized clinical trial

Finland

Therapeutic use (Phase IV) EU CTIS Study details

Death trials by city

Death in Toronto Death in Vancouver Death in Montreal Death in Calgary Death in Edmonton Death in Ottawa Death in Winnipeg Death in Quebec City Death in Hamilton Death in Kitchener Death in London Death in Halifax Death in New York Death in Los Angeles Death in Chicago Death in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease